Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy

BACKGROUND: Long-acting muscarinic antagonist/long-acting β(2)-agonist (LAMA/LABA) provide greater improvements in lung function and symptoms than inhaled corticosteroid (ICS)/LABA in patients with chronic obstructive pulmonary disease (COPD). This study evaluated symptom burden and Global Initiativ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Chron Obstruct Pulmon Dis
Main Authors: Moretz, Chad, Hahn, Beth, White, John, Goolsby Hunter, Alyssa, Essoi, Breanna, Elliott, Caitlin, Ray, Riju
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7605915/
https://ncbi.nlm.nih.gov/pubmed/33149569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S265037
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados